<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82807">
  <stage>Registered</stage>
  <submitdate>8/05/2008</submitdate>
  <approvaldate>8/05/2008</approvaldate>
  <actrnumber>ACTRN12608000238370</actrnumber>
  <trial_identification>
    <studytitle>Inspiratory Training in Amyotrophic Lateral Sclerosis - a phase III, multi-centre, double-blind, randomised-controlled trial</studytitle>
    <scientifictitle>Inspiratory muscle training in amyotrophic lateral sclerosis to improve inspiratory muscle strength</scientifictitle>
    <utrn />
    <trialacronym>2 INSPIRATIonAL</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Amyotrophic lateral sclerosis</healthcondition>
    <healthcondition>Motor neuron disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Inspiratory muscle training - similar to resistance training of limb muscles except the target muscle group is the inspiratory muscles. Inspiratory muscle training involves inhaling through an threshold inspiratory muscle training device for 10 minutes, three times per day for 32 weeks.</interventions>
    <comparator>Sham inspiratory muscle training</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sniff nasal inspiratory pressure.</outcome>
      <timepoint>Weeks 0, 8, 16, 24 and 32.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Respiratory function (forced vital capacity, vital capacity, forced expiratory volume in one second)</outcome>
      <timepoint>Weeks 0, 8, 16, 24 and 32.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health-relatd quality of life (Short Form 36)</outcome>
      <timepoint>Weeks 0, 4, 8, 12, 16, 20, 24, 28 and 32.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related quality of life (Chronic Respiratory Questionnaire)</outcome>
      <timepoint>Weeks 0, 4, 8, 12, 16, 20, 24, 28 and 32.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Grip strength using a handheld Jamar dynamometer</outcome>
      <timepoint>Weeks 0, 4, 8, 12, 16, 20, 24, 28 and 32.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amyotrophic Lateral Sclerosis Functional Rating Scale-revised</outcome>
      <timepoint>Weeks 0, 4, 8, 12, 16, 20, 24, 28 and 32.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6 minute walk test</outcome>
      <timepoint>Weeks 0, 8, 16, 24 and 32.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival</outcome>
      <timepoint>Patient survival will be monitored from the time at which they enter the study till the end of the 32 week training period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Definite, probable or possible amyotrophic lateral sclerosis according to the revised El Escorial criteria. Disease duration of less than 3 years &amp; sniff nasal inspiratory pressure of equal to or greater than 40% predicted. OR disease duration of more than 3 years &amp; sniff nasal inspiratory pressure less than 40% predicted.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who anticipate that they will not be able to use the IMT device over the entire training period.
Tracheostomy ventilation or non-invasive ventilation for greater than 14 hours/day.
Diagnosis of a significant co-existing respiratory or neurological illness.
History of an unstable medical condition in the preceding three years.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealment by sealed opaque envelopes.</concealment>
    <sequence>Permuted Block Randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Participants are blinded to whether they are receiving sham or treatment intervention. The assessor is blinded to whether the participant was in sham or treatment group. Another independent analyst will assess the data and will be blind to whether participants were from sham or treatment groups.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>9/05/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>126</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2031</postcode>
    <postcode>3162</postcode>
    <postcode>4029</postcode>
    <postcode>2065</postcode>
    <postcode>2144</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Australian Rotary Health Research Fund</primarysponsorname>
    <primarysponsoraddress>Australian Rotary Health Research Fund
Floor 2
Rotary Down Under House
43 Hunter Street
PARRAMATTA NSW 2150</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Australian Rotary Health Research Fund</fundingname>
      <fundingaddress>Australian Rotary Health Research Fund
Floor 2
Rotary Down Under House
43 Hunter Street
PARRAMATTA NSW 2150</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Royal Brisbane and Women's Hospital</othercollaboratorname>
      <othercollaboratoraddress>Butterfield Street
Herston QLD 4029</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney Central Coast Area Health Service Human Research Ethics Committee (Harbour)</ethicname>
      <ethicaddress>Research Office
Level 4, Vindin House
Royal North Shore Hospital
Pacific Highway
St. Leonards
NSW 2065</ethicaddress>
      <ethicapprovaldate>1/05/2008</ethicapprovaldate>
      <hrec>0803-021M</hrec>
      <ethicsubmitdate>18/02/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Matthew Kiernan</name>
      <address>Institute of Neurological Sciences
Prince of Wales Hospital
NSW 2031</address>
      <phone>(02) 9382 2422</phone>
      <fax>(02) 9382 2437</fax>
      <email>M.Kiernan@unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Matthew Kiernan</name>
      <address>Institute of Neurological Sciences
Prince of Wales Hospital
NSW 2031</address>
      <phone>(02) 9382 2422</phone>
      <fax>(02) 9382 2437</fax>
      <email>M.Kiernan@unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Benjamin Cheah</name>
      <address>Prince of Wales Medical Research Institute
Corner of Easy and Barker Streets
Randwick NSW 2031</address>
      <phone>(02) 9399 1046</phone>
      <fax>(02) 9382 2437</fax>
      <email>z3058569@student.unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>